Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRONTIER3 pediatric Mim8 prophylaxis study in haemophilia A
NL-OMON51874Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of denecimig in hemophilia A (2 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment-emergent adverse events. Started Jul 2022; status: completed.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON51874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51874.